Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Document › Details

Genedata AG. (9/11/19). "Press Release: Orion Pharmaceuticals Implements Genedata Biologics to Support New Large-Molecule R&D Initiative". Basel.

Organisations Organisation Genedata AG
  Group Genedata (Group)
  Organisation 2 Orion Pharma (division)
  Group Orion Corporation (Group)
Products Product Genedata Biologics® software
  Product 2 biopharmaceutical
Index term Index term Orion Corp–Genedata: bioinformatics, 201909– supply license to Genedata Biologics as SaaS for large-molecule r+d to Orion Pharma
Person Person Pfannes, Othmar (Genedata 200406 CEO)
     


Genedata Biologics to accelerate antibody discovery and streamline R&D operations at Finland’s largest biopharma company


Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced Orion Pharma, a globally operating Finnish pharmaceutical company, has licensed Genedata Biologics® to support their R&D in the areas of oncology, the central nervous system, and other medical indications.

“As part of our strategy to expand our biopharmaceutical R&D operations, we are implementing Genedata as our central workflow backbone to streamline our large-molecule R&D processes,” said Tim Holmström, Head of Biologics at Orion Pharma. “Genedata Biologics was the obvious choice because it is a proven, off-the-shelf enterprise platform that can be rapidly deployed across our organization. Also, collaborating with CROs is a key part of our strategy, so we require an open and scalable system able to capture and integrate all data generated by our CRO network. Finally, Genedata’s offering of Software-as-a-Service (SaaS) was an additional plus because we wanted a self-maintaining model that provides regular upgrades of new, innovative functionalities.”

Genedata Biologics enables Orion scientists to easily capture, process, and interpret all large-molecule R&D data and facilitate the design of antibodies. Further, it integrates all assay and analytics data to enable a comprehensive assessment of all drug candidates. The platform helps eliminate error-prone manual processes by providing a robust, standardized data repository that can be integrated with laboratory instrumentation. All molecule, sample, assay and analytics data, including developability and manufacturability data, are managed within one fully integrated system and are shared between different project teams and sites. The platform facilitates systematic and transparent decision-making to select drug candidates to be progressed through the development pipeline.

“We are very pleased that Orion, an innovative R&D-based pharmaceutical company, has selected Genedata Biologics as their workhorse platform for their biopharma R&D operations. By providing Orion with a backbone that covers their entire discovery pipeline in a single system, we help to increase the efficiency of their R&D processes and speed up decision making,” said Dr. Othmar Pfannes, CEO of Genedata. “Our technology, combined with Orion’s unique scientific approach, will bring cutting-edge therapeutics to patients faster and help them live better and longer lives.”


About Genedata

Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, Singapore, and the US.
www.genedata.com

Follow Us on LinkedIn


Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.


Press Contact

Allison Kurz
Public Relations
+41 61 511 8459
pr@genedata.com

   
Record changed: 2019-09-18

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Genedata (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe 2019 Hamburg Germany BEU2019 650x80px




» top